REDWOOD CITY, Calif., December 14, 2022 (GLOBE NEWSWIRE) — PROCEPT^® BioRobotics Corporation PRCTa surgical robotics company focused on improving patient care through the development of transformative solutions in urology, announced today that members of management at the upcoming 41st…^St Annual JP Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 10 at 9:45 a.m. Pacific Time. A live webcast of the event, as well as an archived recording, will be available in the Investors section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for playback for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on improving patient care through the development of transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced image-guided robotic surgical system for use in minimally invasive urological surgery with an initial focus on the treatment of benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease, affecting approximately 40 million men in the United States. PROCEPT developed Aquablation Therapy to provide effective, safe and lasting results for men suffering from lower urinary tract symptoms or LUTS due to BPH, regardless of prostate size and shape or surgeon experience. The company has developed a significant and growing body of clinical evidence, including nine clinical studies and over 100 peer-reviewed publications, demonstrating the utility and clinical benefits of aquablation therapy.

Investor contact:
Matt Bacso, CFA
VP, Investor Relations and Operations
m.bacso@PROCEPT-BioRobotics.com